Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

  • Technology appraisal guidance
  • TA287
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre (SHTAC):

  • Copley V, Pickett K, Cooper K et al. Rivaroxaban for the treatment of pulmonary embolism and the prevention of recurrent venous thromboembolism. A single technology appraisal. February 2013

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope. Manufacturers or sponsors were also invited to make written submissions. Professional or specialist and patient or carer groups gave their expert views on rivaroxaban by providing a written statement to the Committee. Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, have the opportunity to appeal against the final appraisal determination.

Manufacturer or sponsor

  • Bayer (rivaroxaban)

Professional or specialist and patient or carer groups:

  • AntiCoagulation Europe (ACE)

  • British Society for Haematology

  • British Society for Haemostasis and Thrombosis

  • Clinical Leaders of Thrombosis (CLOT)

  • Lifeblood: The Thrombosis Charity

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

  • Vascular Society

Other consultees:

  • Department of Health

  • Welsh Government

Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • National Clinical Guidelines Centre

  • National Institute for Health Research Health Technology Assessment Programme

  • Southampton Health Technology Assessment Centre, University of Southampton

The following individuals were selected from clinical specialist and patient expert nominations from the consultees and commentators. They gave their expert personal view on rivaroxaban by providing oral evidence to the Committee.

  • Dr David Bevan, Consultant Haematologist and Clinical Lead in Haemostasis, nominated by organisation representing Royal College of Pathologists and British Society for Haematology – clinical specialist

  • Dr Mark Crowther, Consultant Haematologist, nominated by organisation representing British Society of Haemostasis and Thrombosis – clinical specialist

  • Mrs Annya Stephens-Boal, Executive Officer of Lifeblood: The Thrombosis Charity, nominated by organisation representing Lifeblood: The Thrombosis Charity – patient expert

Representatives from the following manufacturer or sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Bayer

ISBN 978-1-4731-0140-1